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Abstract
Earlier studies by our group showed that fructose-1,6-bisphosphate (FBP) enhances the hypothermic preservation of rat
cardiac myocytes and the functional recovery of animal hearts after hypothermic storage. However, the mechanisms
involved were not clear. We extended the cardiomyocyte studies by testing whether the FBP effects were due to chelation
of extracellular calcium, leading to lower intracellular levels. We also tested effects of 2,3-butanedione monoxime (BDM),
pyruvate, and adenine nucleotide precursors. Cardiomyocytes were incubated in ischemic suspension at 3uC, and aliquots
examined over 48 to 72 hours for retention of rod-shaped morphology, a measure of viability. Cytosolic Ca
2+ levels were
measured in some experiments. FBP at 5 mM reduced the death rate even when added after one or two days of incubation.
It caused cytosolic calcium levels that were 33% lower than controls in freshly-isolated cells and 70% lower after one day of
incubation. EGTA protected against cell death similarly to FBP. These results indicated that one of the mechanisms by which
FBP exerts protective effects is through chelation of extracellular calcium. BDM was strongly protective and reduced
cytosolic calcium by 30% after one day of incubation. As with FBP, BDM was effective when added after one or two days of
incubation. BDM may be useful in combination with FBP in preserving heart tissue. Pyruvate, adenine, and ribose provided
little or no protection during hypothermia.
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Introduction
Heart transplantation is a life saving procedure for patients with
end-stage heart failure. However, techniques for heart preserva-
tion have changed very little over decades [1]. Current
hypothermic preservation is still limited to 4–6 hours, not much
better than what was obtained five decades ago. To increase
myocardial survival times, various additives have been proposed
[2], but the results have not been conclusive. Among these
additives, fructose-1,6-bisphosphate (FBP), 2,3-butanedione mono-
xime (BDM), pyruvate, adenosine, ribose, and adenine have all
been reported to have some effects. Of special interest is FBP,
which has been reported to be useful in protecting a variety of
tissues during ischemia and hypoxia. These include heart (e.g.,
Ref. [3]), liver [4], kidney [5], brain [6], smooth muscle [7], lung
[8], and intestine [9]. New studies concerning benefits of FBP
appear every year (e.g., [10–13]). Our group has characterized
effects of FBP in preserving heart function during hypothermic
storage [3,14–15], and has demonstrated uptake of FBP by cardiac
myocytes [16–17], even at 3uC [17]. We also showed that in an
experimental model for hypothermic heart preservation, isolated
cardiac myocytes maintained in ischemic suspension at 3uC, FBP
greatly reduced the death rate (as measured by loss of rod-shaped
morphology) and helped preserve cellular ATP [18]. In other
papers concerning use of FBP with the heart, the compound has
been included in the preservation solution in a study of continuous
perfusion during cold storage [19], and in clinical trials of
coronary artery bypass graft surgery [20–21].
Several hypotheses have been proposed for the mechanism by
which FBP protects tissues. One possibility is that FBP enters cells
and is used in glycolysis, providing ATP without the necessity of
the two prior ATP-consuming phosphorylation steps. Another is
that FBP exerts its effects via chelation of calcium ions [22]. Other
proposals include allosteric activation of phosphofructokinase and
stimulation of the pentose phosphate pathway. However, none of
the proposals have been definitely established.
Hassinen et al. [22] determined a value of about 3 mM for the
dissociation constant of the Ca
2+-FBP complex. Thus, millimolar
levels of FBP, as used in our previous experiments [18], could
reduce extracellular levels of Ca
2+, which in turn would allow the
myocytes to maintain their intracellular Ca
2+ at lower levels and
reduce the amount of ATP consumed by Ca
2+ transport.
The work described here focused on several additives that have
been reported to be effective in myocardial protection. We paid
specialattention tothecalciumchelation hypothesisforFBP effects,
again using isolated cardiac myocytes as an experimental system.
Our results indicate that chelation of extracellular calcium is an
importantpotentialmechanismbywhichFBPprotectscells.Wealso
tested whether 2,3-butanedione monoxime (BDM) and pyruvate,
both of which have shown protective effects with intact heart and
with cardiac myocytes, would be beneficial in our experimental
system. BDM was strongly protective, while pyruvate had little
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either individually or in combination, could enhance the survival of
the myocytes due to their ability to serve as precursors for adenine
nucleotides. The results did not support this hypothesis.
Materials and Methods
Animals
AnimalprotocolswereapprovedbytheInstitutionalAnimalCare
andUseCommitteeoftheUniversityofLouisville(Proposal04152).
Reagents
Collagenase was from Worthington Biochemical Corporation
(Lakewood, NJ) (collagenase type II) or from Roche Applied
Science (Indianapolis, IN) (Liberase Blendzyme 2). Albumin,
ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(2-
aminoethylether)-N,N,N9,N9-tetraacetic acid (EGTA), 2,3-butane-
dione monoxime (BDM), pyruvic acid, and ribose were from
Sigma Chemical Co. (St. Louis, MO). Fructose-1,6-bisphosphate,
trisodium salt, was a gift from Paul J. Marangos, PhD, of Cypros
Pharmaceutical Co. (Carlsbad, CA). Fura-2AM was from
Molecular Probes (Eugene, OR) and adenine from ICN
Biomedicals (Aurora, OH).
Preparation of Cardiac Myocytes
Quiescent, calcium-tolerant cardiac myocytes (typically about
70–80% rod-shaped) were prepared by a modification [23] of the
method of Fischer et al. [24] using male Sprague-Dawley rats, as
in our previous study [18]. The final washes and cell suspensions
were performed using medium E of Fischer et al. [24], consisting
of 6 mM KCl, 1 mM Na2HPO4, 0.2 mM NaH2PO4, 1.4 mM
MgSO4, 128 mM NaCl, 10 mM sodium (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), pH 7.4, and 2% fatty
acid-free albumin.
Assay of Myocyte Preservation
Hypothermic preservation of cardiac myocytes was assayed as
before [18]. Retention of rod-shaped morphology was used as
a measure of viability [25]. Briefly, washed cells were suspended to
concentrations of about 2 to 3610
5/ml in medium E (see above)
plus other compounds being tested. Each compound (or the
combination of adenine plus ribose) other than FBP was tested
both in the presence and absence of 5 mM FBP within the same
experiment, and each experiment included two controls (no
additions) plus one sample with 5 mM FBP tested alone. In most
experiments, eight aliquots of 100 ml for each test condition were
placed in microcentrifuge tubes (0.5 ml) and incubated in
a refrigerator (3uC); these were resuspended and counted at
various time points over a 72 hour period. For the experiments
with BDM, five aliquots of 50 ml for each condition were counted
at various time points over 48 hours. At each time point, an
aliquot was resuspended and two separate samples taken for
counting with a hemacytometer, with total and rod-shaped cell
numbers recorded. Samples were blinded prior to counting (except
for the experiments in which FBP or BDM were added after one
or two days of hypothermic incubation). The data were fitted by
nonlinear regression (using either GraphPad Prism 4 or the Solver
feature of Microsoft Excel) to the equation for first-order decay:
f(t)~f0e{kt
where f(t) is the fraction of rod-shaped cells at time t, f0 the fraction
at time zero, and k the first-order rate constant. The rate constant
was then compared to the average of the rate constants for the two
control incubations within the same experiment (given the same
hypothermic incubation but with no additions to the medium) to
obtain a relative death rate. These relative rates were then
averaged over all experiments to give the values presented in the
figures.
Assays of Intracellular Calcium
Intracellular calcium levels were measured by a modification of
the procedures of Wan and Dean [26]. Cells previously incubated
in medium with or without 5 mM FBP or 5 mM BDM were
concentrated to 10
6 cells/ml in the same medium plus 1 mg/ml
fura-2AM. After a 30 min incubation, the cells were washed
3 times with medium (with the same concentration of FBP or
BDM) and diluted to 1.25610
5 cells/ml. Fluorescence was
measured in a Perkin Elmer LS50B Luminescence Spectrometer
with FL WinLab software (version 3). Excitation alternated
between 340 and 380 nm, while emission was measured at
510 nm. After obtaining a stable sample reading, 20 mM digitonin
and 1 mM CaCl2 were added to obtain the maximal Ca
2+ signal,
followed by addition of 50 mM EGTA to determine the minimal
signal. Calcium concentrations were calculated from the emission
data using the Grynkiewicz equation [27] as described [26].
Assays of Calcium in Media
Calcium concentrations in media were estimated by two
different methods. In the first, fluorescence of diluted samples
was measured using the Fura-2 Calcium Imaging Calibration Kit
from Invitrogen. A calibration curve was constructed using the
InCyt Im2 software. In the second, atomic absorption was
measured using the Perkin Elmer AAnalyst 100 Spectrometer. A
diluted sample (1.8 ml) was mixed with 0.9 ml of 40% nitric acid
and 0.3 ml of LaCl3 (0.1 g/ml). This was centrifuged (446g for
10 min) to precipitate the protein. The supernatant was removed
and subjected to a second centrifugation prior to making the
atomic absorption measurement. A calibration curve was
constructed using Ca
2+ samples of known concentration.
Statistical Analysis of Data
Calculations were performed using the QuickCalcs site of
GraphPad Software (http://graphpad.com/quickcalcs/index.
cfm). Paired t-tests using the individual rates were employed for
analyzing death rates. A sign test was used for analyzing the effect
of FBP on cytosolic calcium.
Results
Effects of FBP Addition After One or Two Days of
Hypothermic Incubation
In our previous study [18], we observed that fructose-1,6-
bisphosphate greatly reduced the loss of viability (as indicated by
rod-shaped morphology) in rat cardiac myocytes kept in ischemic
suspension at 3uC. Retention of rod-shaped morphology is highly
correlated with dye exclusion, a common measure of viability [25].
The optimum concentration of FBP was about 5 mM, which
reduced the death rate by about 65%. In these experiments the
FBP was added to the cells immediately before the cells were
placed in a refrigerator. We were interested in whether the
protective effect of FBP required its presence during the transition
from room temperature to 3uC, or whether it would be protective
even if added later. In the experiments shown in Fig. 1, myocytes
were initially incubated with (triangles) or without (circles) 5 mM
FBP. As was typically seen, FBP greatly reduced the loss of rod-
shaped morphology over the next 72 hours. When FBP was added
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rod-shaped morphology was observed over the next 48 hours,
compared to the control cells, which continued to change their
morphology. In one of the experiments, FBP was also added after
48 hours of incubation, and the morphology was preserved over
the next 24 hours (data not shown).
These results suggested either that FBP could be taken up and
metabolized, giving protective effects, even at 3uC; or that it
exerted its protective effects through other mechanisms not
requiring metabolism. One such mechanism that has been
proposed is chelation of calcium [22].
Effects of Calcium and Chelating Agents on Myocyte
Preservation
The medium used for the hypothermic preservation experi-
ments, medium E (see above, ‘‘Preparation of Cardiac Myocytes’’),
contains no calcium other than that contributed by the albumin. A
test of the effects of additional calcium indicated that levels up to
10 mM had little effect, but levels of 30 mM and higher greatly
increased the death rate (data not shown). We performed two
experiments in which 100 mM calcium was added, with or without
FBP (5 mM) or EDTA (0.5 mM). Results are shown in Fig. 2. The
added calcium more than doubled the death rate (first bar).
However, in the presence 100 mM calcium and either FBP (4th
bar) or EDTA (5th bar), the death rate was lower than in control
cells (no additions), and was nearly as low as with FBP alone (2nd
bar). EDTA alone (3rd bar) also protected similarly to FBP alone.
Thus, either FBP or EDTA can overcome the damaging effects of
a large increase in the medium calcium level.
Additional experiments were performed using EGTA, which is
more specific for calcium chelation. We measured preservation of
myocytes in the presence or absence of EGTA (both with and
without 5 mM FBP) (Fig. 3). EGTA alone (solid bars) reduced the
death rate by about 60% at 0.3 mM and 70% at 1.0 mM. It
appeared that the combination of EGTA and FBP (hatched bars)
offered greater protection than FBP alone (furthest left hatched
bar). Paired t-tests gave p=0.040 for 0.3 mM EGTA plus FBP vs.
FBP alone and p=0.066 for 1 mM EGTA plus FBP vs. FBP
alone. A 77% reduction in the death rate was observed with 1 mM
EGTA plus FBP.
Effects of FBP on Cytosolic Calcium Levels
In order to test whether the effects of FBP on preservation were
related to intracellular calcium levels, we incubated freshly
prepared myocytes with or without 5 mM FBP plus the cell-
permeable Ca
2+ indicator fura-2AM (which is cleaved to the
impermeable fura-2 inside the cell). The cells were then washed
and the fluorescence measured to determine the cytosolic free
Ca
2+ levels. Results of five experiments are shown in the first two
data sets of Fig. 4, which plots the individual results. While the raw
values differ considerably among experiments, in all five experi-
ments the FBP-treated cells (upward pointing triangles) had lower
calcium levels than the controls (filled squares) (p,0.05 by sign
test). When the ratio (FBP-treated vs. control) within each
experiment was averaged over all experiments, a reduction in
calcium of 3367% was seen.
Figure 1. Effects of FBP addition after one day of hypothermic
incubation. Cardiac myocytes were incubated at 3uC for the time
indicated on the x-axis, with additions of 5 mM fructose-1,6-bispho-
sphate prior to the beginning of the incubation (triangles) or after one
day (squares); controls (circles) had no addition. The percentage of rod-
shaped cells at each time point is shown. Results are means from two
experiments. Error bars indicate the individual values (in some cases the
bars lie within the symbols).
doi:10.1371/journal.pone.0035023.g001
Figure 2. Effects of calcium and EDTA on hypothermic
preservation of cardiac myocytes. Cells were incubated with no
additions or with 100 mM calcium, 5 mM FBP, 0.5 mM EDTA, or various
combinations of additions. Death rates for treated cells were
normalized to those of control cells. The averages of the relative death
rates for two experiments are plotted, with error bars indicating S.E.M.
doi:10.1371/journal.pone.0035023.g002
Figure 3. Effects of EGTA on hypothermic preservation. In this
figure and in Figure 5, death rates for treated cells were normalized to
those of control cells in the same experiment, and the relative death
rates averaged over all experiments. Filled bars in these figures are for
treatments without FBP, while hatched bars are for treatments
including 5 mM FBP. Results are means of 4 determinations; error bars
indicate S.E.M. In this figure, myocytes were incubated with the
indicated concentrations of EGTA. Statistically significant by paired t-
tests: **, p,0.01 vs. control; ***, p,0.005 vs. control; +,p ,0.05 vs. FBP
alone.
doi:10.1371/journal.pone.0035023.g003
Protection of Cardiac Myocytes by FBP and BDM
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35023We also examined calcium levels in myocytes that had been
incubated at 3uC for 24 h with or without 5 mM FBP (Fig. 4, third
and fourth sets of data). Again, the calcium levels were in every
case lower (by an average of 70611%, p,0.005) for FBP-treated
cells (diamonds) than for controls (downward pointing triangles).
The mean concentrations were 29 nM for FBP-treated cells vs.
110 nM for controls.
Calcium Levels in Media
The similarity of the protective effects of FBP and EGTA
supports the role of chelation of extracellular Ca
2+ in the
preservation, even though the final medium (medium E) is
prepared without calcium. We attempted to measure the levels
of Ca
2+ typically present in our incubation medium by two
different methods. Our survival experiments were performed with
a constant level of albumin (2%). However, to assess possible
contributions of the albumin to calcium in the media we tested
samples with 1% or 3% albumin. We first employed a fluorescence
method using a fura-2 calcium imaging calibration kit. Various
aliquots of the media gave calculated concentrations of 1 to 8 mM
Ca
2+ for the undiluted media, and the levels were higher for media
with 3% albumin compared to those with 1% albumin. However,
the calculated original concentrations were higher when larger
aliquots were assayed, so the actual values could not be
determined. The second method was atomic absorption. For
these a sample of medium without albumin was also tested. These
measurements gave much higher calculated concentrations (50 to
200 mMC a
2+) for the undiluted albumin-containing media, but
these samples had to be centrifuged twice to remove precipitates,
and possibly some residual precipitated material gave anomalously
high readings. Nevertheless, the results agreed with the fluores-
cence method insofar as 3% albumin gave higher readings than
1% albumin. A sample of albumin-free medium gave a calculated
concentration of 0.3 mM, indicating that the albumin is the major
source of calcium in the incubation medium.
Effects of BDM on Preservation and Cytosolic Calcium
Fig. 5 shows the effects of 1 to 15 mM 2,3-butanedione
monoxime, in the presence and absence of 5 mM FBP, on the
hypothermic preservation. At 2.5 mM and higher, BDM alone
(solid bars) greatly decreased the death rate (p,0.005 for 15 mM
and P,0.002 for 2.5 and 5 mM); the decrease was about 75% at 5
and 15 mM. Moreover, the combination of 15 mM BDM plus
5 mM FBP (hatched bar at far right) produced a decrease of 94 6
7%, which was significantly greater (p,0.05) than the effect of
FBP alone (furthest left hatched bar). We tested whether the effects
of BDM required that it be added at the initiation of the
incubation, performing experiments similar to those done with
FBP (Fig. 1). The results (Fig. 6) show that addition of BDM even
after one or two days of hypothermic incubation was protective.
(Although it appears that the addition of BDM after two days
resulted in an increase in the fraction of rod-shaped cells, this
merely reflects the variation in counts between different aliquots. A
given aliquot, once counted, was not used further.).
We also examined the effect of BDM on cytosolic calcium levels
after 24 h of hypothermic preservation (Fig. 4, fifth and sixth sets
of data). In three experiments, BDM (5 mM) (open squares)
reduced the calcium levels by 29618% compared to cells
incubated for the same time without BDM (circles). This was
a much smaller effect than observed with 24 hours of FBP
treatment (Fig. 4, diamonds vs. downward pointing triangles), even
though the effect of 5 mM BDM on preservation appeared
somewhat greater than that of 5 mM FBP (Fig. 5, fourth solid bar
compared to first hatched bar).
Effects of Pyruvate, Adenine, and Ribose on Myocyte
Preservation
In other experiments testing potential metabolic interventions
for hypothermic preservation, we examined effects of pyruvate,
adenine, and ribose. Pyruvate was tested at 2, 5, and 10 mM, in
both the presence and absence of 5 mM FBP (data not shown). In
the absence of FBP, pyruvate appeared to produce modest
protective effects (10–20% decrease in the death rate). However,
the differences from control were not statistically significant. In the
presence of FBP, no benefits were observed beyond those of FBP
alone.
In order to test whether the adenine nucleotide precursors
adenine and ribose could enhance preservation, we studied the
effects of these two compounds (0.5 to 10 mM) individually; in
equimolar combination with each other; and in combination with
5 mM FBP (data not shown). No significant protective effects were
observed for adenine and/or ribose without FBP, and the
Figure 4. Effects of FBP and BDM on intracellular calcium.
Aliquots of myocytes were given no additions, 5 mM FBP, or 5 mM
BDM, and analyzed for intracellular Ca2+ either immediately or after
24 hours of incubation at 3uC. Individual results are plotted, with means
of the groups indicated by horizontal lines. The first two sets of data are
for five experiments with fresh myocytes without (&) or with (m) FBP.
The second two sets of data are for four experiments with myocytes
incubated for one day without (.) or with (¤) FBP. The last two sets of
data are for three experiments with myocytes incubated for one day
without (N) or with (%) BDM.
doi:10.1371/journal.pone.0035023.g004
Figure 5. Effects of 2,3-butanedione monoxime on preserva-
tion. Myocytes were incubated with the indicated concentrations of
BDM with or without 5 mM FBP. Results are means of 3 determinations.
Statistically significant by paired t-tests: ***, p,0.005 vs. control; ****,
p,0.002 vs. control; +,p ,0.05 vs. FBP alone.
doi:10.1371/journal.pone.0035023.g005
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FBP. The combination of 10 mM adenine plus 10 mM ribose
appeared to increase the death rate, though the effects were not
statistically significant.
Discussion
Possible Protective Effects of FBP Due to Chelation of
Calcium
We observed that 5 mM FBP could protect myocytes from
death during ischemic, hypothermic incubation even if added after
one day (Fig. 1) or two days. This suggested that a mechanism
other than metabolism of FBP might be involved in its protective
effects, with chelation of extracellular calcium by FBP being
a possibility [22]. Although the myocytes are referred to as
"calcium tolerant" because they survived increasing amounts of
calcium during the isolation procedure [24], the final preparation
nevertheless shows reduced viability during hypothermic in-
cubation with added calcium (Figure 2). Likely this is because
increasing extracellular calcium will lead to a rise in intracellular
calcium. The latter can be damaging via several mechanisms,
including expenditure of ATP for Ca
2+ATPases, as the cells
attempt to lower their cytosolic calcium levels; activation of
contractile activity, also reducing ATP; and activation of Ca
2+-
dependent proteinases. By reducing the extracellular Ca
2+ level,
FBP would make it easier for cells to maintain low intracellular
levels and prevent such damage.
In the experiments shown in Fig. 3, the calcium-chelating agent
EGTA reduced the death rate by 60–70%, similar to the effects of
FBP. Thus, chelation of calcium is protective in our experimental
system, even though the final medium used to wash and incubate
the myocytes (medium E) is nominally calcium-free. It is difficult to
measure the levels of calcium in this medium. However, the results
indicated that the medium likely contained micromolar levels of
calcium, and that most of this probably came from the albumin.
Thus, the idea of a chelating effect of extracellular FBP is
reasonable. Using a dissociation constant of 3 mM [22], 5 mM
FBP would bind approximately 60% of the calcium in the
medium. We found that there was considerable variation in the
quality of myocytes prepared using different lots of albumin having
the same product number. Possibly this was the result of
differences in calcium content of the different batches.
Evidence for effects of FBP on calcium homeostasis is shown in
Fig. 4. For freshly-prepared myocytes (first two sets of data),
cytosolic calcium was an average of 33% lower in FBP-treated cells
(upward pointing triangles) compared to control cells (solid
squares). For freshly-prepared cells there is expected to be little
effect of FBP on the cellular ATP levels; in Ref. [18] we observed
only a 16% higher ATP level for cells treated with 5 mM FBP
compared to control cells after 2 hours of hypothermic incubation.
Thus, the differences for the fresh myocytes in Fig. 4 are likely
direct effects of calcium chelation rather than due to increased
availability of ATP for Ca
2+ pumping. Our earlier experiments
[18] found that ATP levels were about 30% higher at 6 hours and
50% higher at 24 hours in FBP-treated cells. Therefore the larger
reduction in calcium with 24 hours of FBP treatment (Fig. 4,
diamonds vs. downward pointing triangles) may be due to both
chelation of Ca
2+ by FBP and the cumulative effects of
maintaining higher ATP levels in the cells, which should allow
them to reduce the calcium levels through Ca
2+-ATPase activity.
In addition to producing extracellular effects, it is possible that
FBP could be taken up by the cells and chelate intracellular Ca
2+.
We previously showed that label from radiolabeled FBP at 5 mM
could be taken up by myocytes, both at room temperature and at
3uC [15]. However, it is likely that much of this label was
converted to other metabolites, and it seems unlikely that
intracellular FBP would rise to levels high enough to provide
a significant chelating effect.
Additional support for a chelating effect of extracellular FBP,
rather than an effect via glycolytic ATP production, comes from
a comparison of the effects of BDM and FBP. These compounds at
5 mM had similar effects on the hypothermic survival of myocytes
(Fig. 5, first hatched bar vs. fourth filled bar). However, in
myocytes incubated for 24 hours, BDM (which could affect
calcium levels indirectly by preserving ATP) produced a much
smaller reduction in free calcium (Fig. 4, open squares vs. circles)
than did FBP (Fig. 4, diamonds vs. downward pointing triangles).
Nevertheless, the data in Fig. 3 indicate that FBP may have
protective effects beyond those due to calcium chelation. For both
0.3 and 1.0 mM EGTA, it appeared that the combination of FBP
and EGTA (hatched bars) produced greater reductions in the
death rate than EGTA alone (solid bars), although the differences
were not statistically significant at the p,0.05 level by paired t-
tests (p=0.06 and 0.12 for 0.3 and 1.0 mM EGTA, respectively).
Because of the much greater affinity of EGTA for Ca
2+ compared
to the affinity of FBP, 5 mM FBP would not lower the Ca
2+ level
significantly in the presence of these levels of EGTA. We
previously showed that FBP could be taken up by cardiac
myocytes at 21uC and 3uC [17]. It is possible that FBP taken up
during or after the transition to hypothermia could be used to
provide glycolytic ATP (without the need for the ATP-consuming
steps in glycolysis) even at the reduced temperature. Since energy-
consuming processes would also be slowed by the hypothermia,
this ATP could provide significant protection against cell death. As
described above, we previously demonstrated that FBP helped
maintain higher levels of ATP during hypothermic incubation
[18]. It should be noted that Hassinen et al. [22] reported
metabolic effects of FBP in perfused hearts that were not produced
by EGTA and thus did not appear to be due to calcium chelation.
Previous Studies of FBP and Calcium
Effects on Ca
2+ levels are often mentioned as a possible
mechanism of FBP action. Several studies (e.g., Ref. [22]) have
shown reduction in Ca
2+ in extracellular media in the presence of
FBP, but their conclusions differ. Only a few papers have actually
measured changes in intracellular Ca
2+ concentrations due to
Figure 6. Effects of BDM addition after one or two days of
hypothermic incubation. Cardiac myocytes were incubated at 3uC
for the time indicated on the x-axis, with additions of 5 mM 2,3-
butanedione monoxime prior to the beginning of the incubation
(triangles) or after one (squares) or two (diamonds) days; controls
(circles) had no addition. The percentage of rod-shaped cells at each
time point is shown. Results are means from two experiments.
doi:10.1371/journal.pone.0035023.g006
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hypoxia-induced increases in intracellular Ca
2+ in brain slices and
astrocytes. Effects on basal levels were not reported. While the
authors suggested that preservation of ATP was responsible for the
FBP effect, they also suggested that Ca
2+ chelation could be
involved. Cavallini et al. [29] showed that FBP inhibited the
thrombin-induced increase in cytosolic Ca
2+ in platelets, though it
did not appear that there was any effect on the resting Ca
2+ level.
The authors proposed effects on ‘‘the transmission of signal at the
level of the receptor-G-protein-phospholipase C system.’’ Tamaki
et al. [30] reported that FBP inhibited the increase in cytosolic
Ca
2+ in response to phorbol ester treatment of Kupffer cells (data
were reported as fluorescence recordings rather than Ca
2+
concentrations). The authors proposed that the effects came about
via both chelation of extracellular Ca
2+ and by provision of
glycolytic ATP, allowing greater Ca
2+-ATPase activity. Two of the
studies that looked at intracellular Ca
2+ [31–32] concerned
neurons, and found increases in cytosolic Ca
2+ in response to
FBP treatment, in contrast to our observations. However, in Ref.
[31], FBP, while it increased basal Ca
2+ levels, prevented the
increase in Ca
2+ in response to hypoxia. Although chelation of
Ca
2+ was mentioned as possibly contributing to this effect, the
authors concluded that ‘‘chelation does not account for the
entirety of FBP’s protective properties,’’ and they favored
a mechanism involving phospholipase C signaling.
In another study, using synaptosomes rather than intact cells,
Zeng et al. [33] showed that FBP reduced the free Ca
2+ level
during ischemic conditions. They proposed metabolic effects of
FBP and did not address the possible role of chelation.
Thus, our studies add to the weight of evidence concerning
a role for Ca
2+ in protective effects of FBP, and provide the first
experimental evidence related to an effect of FBP on Ca
2+
homeostasis in heart preservation. Possible further experiments
that would help confirm our hypothesis would include determining
the effect of FBP on survival under conditions in which
extracellular Ca
2+ is fixed (using solutions of Ca
2+ and EGTA),
as well as measurements of intracellular Ca
2+ (similar to those in
Fig. 4) for EGTA-treated myocytes. Determining the combined
effect of EGTA and FBP on intracellular Ca
2+ would help
establish whether or not FBP acts by multiple mechanisms.
Effects of BDM
2,3-Butanedione monoxime (BDM) has several effects in the
heart [34]. These include effects on calcium fluxes at low
concentrations and inhibition of myosin ATPase at somewhat
higher concentrations. Beneficial effects of BDM in the prepara-
tion of cardiac myocytes have been characterized [35], and the
compound is used in the procedure we employed [24]. Several
studies (e.g., Ref. [36]) have found benefits in preservation of the
intact heart. However, at high concentrations, BDM can also have
deleterious effects, possibly through action as a phosphatase [34].
We found that BDM produced a marked protective effect
(comparable to that of FBP) during hypothermic incubation of
myocytes (Fig. 5). As was the case for FBP, BDM reduced the
death rate even when added after one or two days of hypothermic
incubation (Fig. 6). Treatment with BDM for 24 hours also
resulted in a lower cytosolic calcium concentration (Fig. 4, open
squares) compared to untreated cells (circles). However, the effect
was much lower than that of FBP (Fig. 4, diamonds vs. downward
pointing triangles). Possibly this is because the effect of BDM on
calcium is indirect; by inhibiting myosin ATPase and preserving
ATP, it enables the cells to maintain calcium pumping activity
better than untreated cells. Because they have different modes of
action, the combination of FBP and BDM may have benefits
beyond either alone, as indicated by the furthest right hatched bar
in Fig. 5.
Kivisto ¨ et al. [37] observed protective effects of BDM (25 mM)
on cardiac myocytes incubated for 24 hours at 5uC, in agreement
with our results. However, these experiments used myocytes
deliberately isolated under ‘‘stressed’’ conditions, such that less
than 1% to 10% of the cells remained viable after 24 hours with
the various treatments. By comparison, in our studies with BDM,
control cells averaged 41% viability after 24 hours, while those
treated with 1 to 15 mM BDM averaged 56% viability.
Effects of Pyruvate, Adenine and Ribose
Pyruvate is employed during the procedure we used for the
preparation of cardiac myocytes [24]. The general metabolic
benefits of pyruvate in the heart have been reviewed by Mallet
[38]. Most studies of pyruvate’s effects on the heart have examined
periods of reperfusion after ischemia, rather than effects during
cold storage. We found that pyruvate produced, at best, relatively
small decreases in the death rate of myocytes incubated at 3uC.
When combined with 5 mM FBP, effects were no greater than
those of FBP alone. While we hypothesized that there might be
sufficient residual oxygen in the ischemic cell suspensions to
support pyruvate oxidation, the results suggest that either such
metabolism is relatively small, or it provides little survival
advantage to the myocytes. This is consistent with our previous
finding that dichloroacetate, which stimulates pyruvate dehydro-
genase, produced no beneficial effects under these conditions [18].
The critical role of maintaining ATP levels in the survival of the
heart during cold storage has long been recognized [39]. Even if
glycolysis is enhanced (e.g., by provision of FBP), the supply of
adenine nucleotides could limit energy production. In addition to
conversion of ATP to ADP and AMP, the total adenine nucleotide
pool can be depleted under ischemic conditions due to the further
degradation to adenosine, inosine, and hypoxanthine, all of which
can penetrate the plasma membrane and be lost to cardiac
myocytes [40]. One strategy for overcoming this problem is to
provide the precursors for de novo adenine nucleotide synthesis,
adenine and ribose. In various studies, these two compounds have
been shown to be beneficial for the heart, either alone or in
combination. However, these experiments have focused on
recovery of function and of ATP during reperfusion, rather than
preservation during a period of cold storage.
We tested whether adenine and ribose, when present during
hypothermic incubation of cardiac myocytes, could reduce their
death rates. Neither adenine nor ribose showed significant effects
whenaddedindividually.Moreover,thecombinationofthetwoalso
was not beneficial. While it is possible that the treatments would aid
in the resynthesis of adenine nucleotides following return to
normoxia and normothermia, it appeared that any synthesis of
adenine nucleotides was insufficient to improve survival while the
cells remained under ischemic, hypothermic conditions.
Conclusions
The results presented here extend our earlier work on the ability
of FBP to preserve cardiac myocytes under hypothermic
conditions [18]. Our findings indicate that one major effect of
FBP is its chelation of extracellular Ca
2+, in addition to other
mechanisms. An appreciation of the ability of FBP to chelate Ca
2+,
and thus affect intracellular calcium levels, is of importance
because FBP has been used for preservation of a wide variety of
types of tissues [3–9], as well as in many other types of
experiments. We used an extreme endpoint for assessing the
effects of FBP (protection against cell death), but it is likely that
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no cell death is occurring.
Recent studies have often focused on diverse pathways that are
altered in response to FBP, such as inflammation [41] and
apoptosis [42]. However, the underlying connection between FBP
and such effects are unclear. Our results suggest two linked
mechanisms for FBP effects: calcium and energy. If FBP acts to
chelate calcium, it will spare ATP that would otherwise be used in
calcium pumping. Alternatively, If FBP is used to provide
glycolytic ATP, the increased cellular energy can help control
intracellular Ca
2+ levels. Together, effects of FBP on ATP and
Ca
2+ levels will influence many regulatory pathways, and these
pathways deserve further exploration.
Also, in the course of our studies we observed that albumin can
contribute significant amounts of calcium to cell culture media,
and that different lots of the same commercial albumin product
appear to differ considerably in their calcium content. This may be
important to researchers employing albumin in situations where
calcium concentration is critical.
BDM also has strong protective effects in our experimental
system. Thus, FBP and BDM may be useful in hypothermic
preservationofheartsfortransplantation.Becausecalciumlevelsare
normally well controlled in vivo, especially in clinical situations,
calcium chelation might be less relevant compared to other
beneficial effects of these two agents. However, during ex vivo
preservation experiments, this could be a major factor in
cardiomyocyte survival. Pyruvate, adenine, and ribose had little or
no beneficial effects during the ischemic, hypothermic incubation.
However, it remains possible that these compounds could be
protective upon return to physiological temperature and oxygen
levels.
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